Lecanemab’s Path Forward: Navigating the Future of Alzheimer’s Treatment in Europe Amidst the EMA's Rejection
Open Access
- 2 November 2024
- journal article
- research article
- Published by Springer Nature in Neurology and Therapy
- Vol. 14 (1) , 1-5
Abstract
Lecanemab (Leqembi©, Biogen), a humanized anti-amyloid-beta monoclonal antibody, has been approved for early-stage Alzheimer’s disease (AD) in several countries, including the US and Japan. However, the European Medicines Agency (EMA) recently issued a negative opinion on its marketing authorization, reflecting concerns over the clinical value and manageability of anti-amyloid treatments. This decision highlights the ongoing disconnect between research advancements and clinical practice, where the focus on biological markers over tangible clinical improvements remains contentious. Despite promising biological effects, lecanemab’s clinical outcomes have been modest, raising questions about its therapeutic role. The EMA’s refusal underscores the need to address doubts surrounding the real-world effectiveness and safety of such treatments, especially concerning amyloid-related imaging abnormalities (ARIAs), a common side effect observed in clinical trials. The recent approval of lecanemab by the UK's Medicines and Healthcare products Regulatory Agency, despite the National Institute for Health and Care Excellence’s rejection on cost-effectiveness grounds, further fuels the debate on the feasibility of anti-amyloid therapies. This commentary emphasizes the importance of real-world data on lecanemab's impact on cognitive decline, daily functioning, and side-effect management. As the global clinical use of lecanemab increases, continuous and standardized reporting on its outcomes is crucial for guiding future regulatory decisions and for potentially bridging the gap between research and practice in AD treatment.Keywords
This publication has 21 references indexed in Scilit:
- Challenges to identifying risk versus protective factors in Alzheimer’s diseaseNature Medicine, 2024
- Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysisAgeing Research Reviews, 2024
- Once upon a time, the Amyloid Cascade HypothesisAgeing Research Reviews, 2023
- Donanemab in Early Symptomatic Alzheimer DiseaseJAMA, 2023
- Passive Alzheimer’s immunotherapy: A promising or uncertain option?Ageing Research Reviews, 2023
- Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer’s diseaseBrain Communications, 2023
- Lecanemab in Early Alzheimer’s DiseaseNew England Journal of Medicine, 2023
- Alzheimer disease neuropathology in a patient previously treated with aducanumabActa Neuropathologica, 2022
- Prevalence of Biologically vs Clinically Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer’s Association Research FrameworkJAMA Neurology, 2019
- Alzheimer's disease: a re-examination of the amyloid hypothesisTrends in Neurosciences, 1998